|
SARS-CoV-2
— The
Battle against Coronavirus has just Begun |
| •
SARS-CoV-2 showed highly pathogenic, caused severe or even
life-threatening diseases, and still transmitted from
person-to-person. |
| • The World Health
Organization declared a global pandemic as the coronavirus
(SARS-CoV-2) rapidly spreads across the world. |
| • Until now, no drugs or
biologics have been proven to be effective for the prevention
or treatment of COVID-19. |
|
SARS-CoV-2
— Promising
Antiviral Agents |
|
Favipiravir
(T-705)
|
Selectively
and potently inhibits the RNA-dependent RNA
polymerase(RdRp) of RNA viruses. Shows good clinical
efficacy in treating COVID-19. |
|
Remdesivir
(GS-5734)
|
A
nucleotide analog inhibitor of RdRp. Against SARS-CoV,
MERS-CoV and Ebola virus. Effectively inhibits
SARS-CoV-2 in vitro. Enters phase III trial.
|
|
Chloroquine
Phosphate
|
An
antimalarial agent. Inhibits autophagy and toll-like
receptors (TLRs). Effectively inhibits SARS-CoV-2 in
vitro. FDA approved. |
|
Hydroxychloro-
quine
sulfate |
An
antimalarial and anti-inflammatory agent. Inhibits
TLR7/9 signaling. Efficiently inhibits SARS-CoV-2
infection in vitro. FDA approved.
| |
| MedChemExpress Anti-COVID-19 Compound Library
based on Relevant Proteins: |
| We conduct Virtual Screening of
approved compound library and clinical compound library based
on 3CLpro (PDB ID: 6LU7), RdRp, Spike Glycoprotein (PDB ID:
6VSB), nsp15 (PDB ID: 6VWW), PLpro and ACE2 Structure. |
| Partial Screening Library Data: |
|
SARS-CoV-2
|
Compounds
|
Information
|
|
3CLpro |
Saquinavir |
An
HIV Protease inhibitor. FDA approved. |
|
Carfilzomib |
An
irreversible proteasome inhibitor. FDA approved.
|
|
Nelfinavir |
An
orally bioavailable HIV-1 protease inhibitor (Ki=2 nM)
and antiviral agent. FDA approved. |
|
S Protein & ACE2
|
Bimosiamose |
A
nonoligosaccharide pan-selectin inhibitor and has anti-
inflammatory effects. Phase 2. |
|
RdRp |
Zanamivir |
An
influenza viral neuraminidase inhibitor. FDA
approved. |
|
nsp15 |
Ribavirin |
An
antiviral agent against a broad spectrum of viruses
including HCV, HIV, and RSV. FDA approved.
|
|
PLpro |
Epetraborole
hydrochloride
|
A
leucyl-tRNA synthetase (LeuRS) inhibitor. Intended for
the infections caused by Gram-negative bacteria. Phase
2. | |
|
|
